Learn more about our CEO and leadership’s backgrounds to see how they drive for great impact across the medical field.
Gene Liau is the chief scientific officer at Stoke Therapeutics. Gene was most recently senior vice president and head of gene therapy R&D at Precision BioSciences. Prior to Precision BioSciences, Gene spent five years at Pfizer where, as executive director, he led external R&D efforts for rare disease and hematology programs and spearheaded the company’s gene therapy initiative. Gene joined Pfizer from Shire, where he helped the company to build an innovative rare disease portfolio. Gene also spent 12 years at Novartis, initially building a research unit focused on using gene therapy for cardiovascular and metabolic applications and eventually leading the cardiovascular/metabolic division at the Novartis Institutes for BioMedical Research in Cambridge, where he was responsible for projects from target discovery to early clinical proof of concept. Prior to entering industry, Gene was a professor at George Washington University Medical Center and also a senior scientist at the Jerome H. Holland Laboratory of the American Red Cross. Gene received his Ph.D. in biochemistry from Vanderbilt University and completed his postdoctoral fellowship at the National Cancer Institute.